Trans-amplifying mRNA Vaccines
Not Specified
Pre-clinicalActive
Key Facts
About ExcepGen
ExcepGen is a private, pre-clinical stage biotech developing a novel platform, RNAx, to create more tolerable RNA vaccines and therapeutics. The platform addresses a key limitation of current nucleic acid medicines—excessive innate immune activation—by encoding a regulatory protein within the mRNA itself. Led by a team with expertise in biochemistry and synthetic biology, the company is advancing initiatives in self-amplifying, trans-amplifying, and conventional mRNA vaccines, aiming to unlock the full potential of RNA-based medicine with a safety profile closer to the standard of care.
View full company profileTherapeutic Areas
Other Not Specified Drugs
| Drug | Company | Phase |
|---|---|---|
| Inflammation Programs | Arcus Biosciences | Not Specified |
| Bone Marrow Conditioning Program | Telix Pharmaceuticals | Pipeline |
| AGMB-447 | Agomab Therapeutics | Not Disclosed |
| AGMB-101 | Agomab Therapeutics | Not Disclosed |
| TRIFERTY-ATM® | Laboratorio Reig Jofre | Approved/Commercial |
| AGEN1571 (anti-ILT2) | Agenus | Not specified |
| AGEN1777 | Agenus | Not specified |
| AGEN1721 | Agenus | Not specified |
| INCAGN1876 (GITR Agonist) | Agenus | Not specified |
| INCAGN1949 (OX40 Agonist) | Agenus | Not specified |
| AGEN1327 (anti-TIGIT) | Agenus | Not specified |
| AGEN2373 (CD137 Agonist) | Agenus | Not specified |